The short version of CJC-1295 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Avian skin is a bit more complicated than the skin of gliding lizards or bats because the presence of feathers. In addition to the counteracting stresses and stains associated with flight, avian skin must provide a means to monitor and anchor a "coat of feathers", thus the structure of avian skin is different from skin of other flying and gliding animals. To better understand the structure of avian skin, avian skin has been broken down into three different functional components:
=== Spatial Localization Sequences === In PRESS, the two chief drawbacks are lengthy echo time (TE) and chemical shift displacement (CSD) artifacts. Lengthy echo time arises from the fact that PRESS uses two 180° pulses, unlike STEAM which uses exclusively 90° pulses. The duration of 180° pulses are generally longer than 90° pulses because it takes more energy to flip a net magnetization vector completely as opposed to only 90°. Chemical shift displacement artifacts arises partly because of less optimal slice selection profiles. Multiple 180° pulses does not allow a very short TE, resulting in less optimal slice selection profile. Additionally, multiple 180° pulses means smaller bandwidth and thus larger chemical shift displacement. Specifically, the chemical shift displacement artifacts occur because signals with different chemical shifts experience different frequency-encoded slice selections and thus do not originate from same volume. Additionally, this effect becomes greater at higher magnetic field strengths. SPECIAL consists of a spatially selective pre-excitation inversion pulse (typically AFP) followed by spatially selective excitation and refocusing pulses, both of which are usually SLR or truncated sinc pulses. SPECIAL is a hybrid of PRESS and Image-Selected In Vivo Spectroscopy (ISIS). ISIS achieves spatial localization in the three spatial dimensions through a series of eight slice-selective preinversion pulses that can be appropriately positioned so that the sum of the eight cycles removes all signal outside the desired 3D region.
== Sources == Bartusis, Mark C. (1997). The Late Byzantine Army: Arms and Society, 1204–1453. University of Pennsylvania Press. ISBN 0-8122-1620-2. Geanakoplos, Deno John (1959). Emperor Michael Palaeologus and the West, 1258–1282: A Study in Byzantine-Latin Relations. Cambridge, Massachusetts: Harvard University Press. Nicol, Donald M. (1993) [1972]. The Last Centuries of Byzantium, 1261–1453 (Second ed.). Cambridge: Cambridge University Press. ISBN 978-0-521-43991-6. Wolff, Robert Lee (1969) [1962]. "The Latin Empire of Constantinople, 1204–1261". In Setton, Kenneth M.; Wolff, Robert Lee; Hazard, Harry W. (eds.). A History of the Crusades, Volume II: The Later Crusades, 1189–1311. Vol. 2 (Second ed.). Madison, Milwaukee, and London: University of Wisconsin Press. pp. 186–233. ISBN 0-299-04844-6.
=== Phrixotoxin-3 === Injection of this venom into mice causes immediate general ataxia, lack to response stimuli and semi-paralysis. Inability to stand and breathing reduction occurs within minutes. Flaccid paralysis and slowing of breathing eventually cause death (Bosmans 2006).
Sources: en.wikipedia.org
==== MeSH D12.776.860.300.250 – collagen ==== MeSH D12.776.860.300.250.300 – fibrillar collagens MeSH D12.776.860.300.250.300.100 – Type I collagen MeSH D12.776.860.300.250.300.200 – Type II collagen MeSH D12.776.860.300.250.300.300 – Type III collagen MeSH D12.776.860.300.250.300.400 – Type V collagen MeSH D12.776.860.300.250.300.500 – Type XI collagen MeSH D12.776.860.300.250.400 – non-fibrillar collagens MeSH D12.776.860.300.250.400.100 – Type IV collagen MeSH D12.776.860.300.250.400.200 – Type VI collagen MeSH D12.776.860.300.250.400.300 – Type VII collagen MeSH D12.776.860.300.250.400.400 – Type VIII collagen MeSH D12.776.860.300.250.400.500 – Type X collagen MeSH D12.776.860.300.250.400.525 – Type XIII collagen MeSH D12.776.860.300.250.400.537 – Type XVIII collagen MeSH D12.776.860.300.250.400.537.500 – endostatins MeSH D12.776.860.300.250.400.550 – fibril-associated collagens MeSH D12.776.860.300.250.400.550.200 – Type IX collagen MeSH D12.776.860.300.250.400.550.300 – Type XII collagen MeSH D12.776.860.300.250.600 – procollagen MeSH D12.776.860.300.250.700 – tropocollagen
Advertisements were a large influence in the marketable appeal of skin whitening in China and Taiwan. Skincare products that are recognized to protect the skin included chemicals that assist in skin whitening. These products were marketed and promoted as the solution to appearing young forever. Skincare products have been predominantly created to serve as anti-aging to women in China and Taiwan of all ages.
In 1923–24 inventor Harry Grindell Matthews repeatedly claimed to have built a device that projected energy over long ranges and attempted to sell it to the War Office, but it was deemed to be fraudulent. His attempts spurred on many other inventors to contact the British military with claims of having perfected some form of the fabled electric or radio "death ray". Some turned out to be frauds and none turned out to be feasible. Around the same time, a series of stories suggested another radio weapon was being developed in Germany. The stories varied, with one common thread being a death ray, and another that used the signals to interfere with an engine's ignition system to cause the engine to stall. One commonly repeated story involved an English couple who were driving in the Black Forest on holiday and had their car fail in the countryside. They claimed they were approached by soldiers who told them to wait while they conducted a test, and were then able to start their engine without trouble when the test was complete. This was followed shortly thereafter by a story in a German newspaper with an image of a large radio antenna that had been installed on Feldberg in the same area. Although highly skeptical about claims of engine-stopping rays and death rays, the Air Ministry could not ignore them as they were theoretically possible. If such systems could be built, it might render bombers useless. If this were to happen, the night bomber deterrent might evaporate overnight, leaving the UK open to attack by Germany's ever-growing air fleet.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.